Clinical trial
Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
NCT00498368 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00498368 |
|---|---|
| Title | Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy |
| Official title | A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | Ohio State University Stanford University University of North Carolina, Chapel Hill Columbia University Genentech, Inc. Industry Biogen |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | IgA Nephropathy |
| Intervention type | Dietary Supplement, Drug |
| Interventions | Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement |
| Enrollment | 34 |
| Start date | Feb 1, 2009 |
| Primary completion | Sep 1, 2015 |
| Completion | Sep 1, 2015 |
| First posted | Jul 10, 2007 |
| Last update posted | Feb 1, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: